Revista alergia Mexico (Tecamachalco, Puebla, Mexico : 1993) · 2020
[The efficacy and safety of two schemes of desensitization to trimethoprim-sulfamethoxazole in HIV-positive patients].
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hernández-Morales María Rocío, Mancilla-Hernández Eleazar
Аннотация
BACKGROUND: Trimethoprim with sulfamethoxazole (TMP-SMX) is the drug of choice for the prophylaxis of AIDS-associated comorbidities.
OBJECTIVE: To compare the efficacy and safety of two schemes of desensitization to TMP-SMX in HIV-positive patients.
METHODS: A study was conducted from March 2018 to October 2019; it included HIV-positive patients who presented an adverse skin reaction to TMP-SMX; fifteen of them received desensitization scheme 1, which lasted ten days, and five patients received scheme 2, which lasted six hours.
RESULTS: The average age of the patients who received scheme 1 was of 27.4 ± 5.7 years, while the average age of patients who received scheme 2 was of 33.6 ± 8 years. At baseline, the demographic, clinical, and immunological variables did not show significant differences between both groups (p> 0.05). In both groups, an efficacy of 100% was obtained and, in terms of safety, only three patients in group 1 presented rash and pruritus, however, the procedure was not suspended; the previous tolerated dose was resumed and, subsequently, the desensitization procedure continued.
CONCLUSIONS: Both schemes of desensitization to TMP-SMX showed efficacy and safety in HIV-positive patients, who frequently present adverse reactions to these medications.
OBJECTIVE: To compare the efficacy and safety of two schemes of desensitization to TMP-SMX in HIV-positive patients.
METHODS: A study was conducted from March 2018 to October 2019; it included HIV-positive patients who presented an adverse skin reaction to TMP-SMX; fifteen of them received desensitization scheme 1, which lasted ten days, and five patients received scheme 2, which lasted six hours.
RESULTS: The average age of the patients who received scheme 1 was of 27.4 ± 5.7 years, while the average age of patients who received scheme 2 was of 33.6 ± 8 years. At baseline, the demographic, clinical, and immunological variables did not show significant differences between both groups (p> 0.05). In both groups, an efficacy of 100% was obtained and, in terms of safety, only three patients in group 1 presented rash and pruritus, however, the procedure was not suspended; the previous tolerated dose was resumed and, subsequently, the desensitization procedure continued.
CONCLUSIONS: Both schemes of desensitization to TMP-SMX showed efficacy and safety in HIV-positive patients, who frequently present adverse reactions to these medications.